NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2017
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Sponsors Nihon Pharmaceutical
- 01 Oct 2017 Results published in the Journal of Neurology, Neurosurgery and Psychiatry.
- 19 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015, as per ClinicalTrials.gov record.